215 related articles for article (PubMed ID: 37857898)
1. Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis.
Lense XM; Hiemke C; Funk CSM; Havemann-Reinecke U; Hefner G; Menke A; Mössner R; Riemer TG; Scherf-Clavel M; Schoretsanitis G; Gründer G; Hart XM
Psychopharmacology (Berl); 2024 Feb; 241(2):275-289. PubMed ID: 37857898
[TBL] [Abstract][Full Text] [Related]
2. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
3. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
4. Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring.
Stamm TJ; Becker D; Sondergeld LM; Wiethoff K; Hiemke C; O'Malley G; Ricken R; Bauer M; Adli M
Pharmacopsychiatry; 2014 Jul; 47(4-5):174-9. PubMed ID: 25054625
[TBL] [Abstract][Full Text] [Related]
5. Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose-corrected concentrations of venlafaxine and O-desmethylvenlafaxine: A retrospective analysis of therapeutic drug monitoring data in a Chinese population.
Wang ZZ; Deng SH; Lu HY; Li L; Zhu XQ; Hu JQ; Xie HS; Chen HZ; Chen YQ; Zhang M; Fang ZY; Wen YG; Shang DW
Hum Psychopharmacol; 2020 May; 35(3):e2733. PubMed ID: 32239743
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue.
Murrell MD; Cruz DA; Javors MA; Thompson PM
J Forensic Sci; 2014 May; 59(3):683-9. PubMed ID: 24502274
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Paulzen M; Haen E; Hiemke C; Fay B; Unholzer S; Gründer G; Schoretsanitis G
J Affect Disord; 2018 Feb; 227():506-511. PubMed ID: 29156365
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database.
Schoretsanitis G; Haen E; Gründer G; Hiemke C; Endres K; Ridders F; Correll CU; Paulzen M
Eur J Clin Pharmacol; 2019 Aug; 75(8):1109-1116. PubMed ID: 30968172
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy exposure to venlafaxine-Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes.
Paulzen M; Schoretsanitis G; Gründer G; Franz C; Stingl JC; Augustin M
J Affect Disord; 2020 Apr; 266():578-584. PubMed ID: 32056930
[TBL] [Abstract][Full Text] [Related]
11. Multiplexed quantification of venlafaxine and metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Pandey A; Price A; Ayala-Lopez N; Garza KY; Marzinke MA; Knezevic CE
J Pharm Biomed Anal; 2024 Jun; 243():116082. PubMed ID: 38461636
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
Reis M; Lundmark J; Björk H; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
[TBL] [Abstract][Full Text] [Related]
13. Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients.
De Donatis D; Porcelli S; Zernig G; Mercolini L; Giupponi G; Serretti A; Conca A; Florio V
World J Biol Psychiatry; 2022 Mar; 23(3):183-190. PubMed ID: 34096828
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
[TBL] [Abstract][Full Text] [Related]
15. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine.
Kowalewski C; Haen E; Hiemke C; Ridders F; Endres K; Gründer G; Paulzen M; Schoretsanitis G
Int Clin Psychopharmacol; 2019 Sep; 34(5):241-246. PubMed ID: 31094902
[TBL] [Abstract][Full Text] [Related]
17. Reduced clearance of venlafaxine in a combined treatment with quetiapine.
Paulzen M; Schoretsanitis G; Hiemke C; Gründer G; Haen E; Augustin M
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul; 85():116-121. PubMed ID: 29702137
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine versus other anti-depressive agents for depression.
Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
[TBL] [Abstract][Full Text] [Related]
19. Selective solid-phase extraction using molecularly imprinted polymers for analysis of venlafaxine, O-desmethylvenlafaxine, and N-desmethylvenlafaxine in plasma samples by liquid chromatography-tandem mass spectrometry.
Miranda LF; Domingues DS; Queiroz ME
J Chromatogr A; 2016 Aug; 1458():46-53. PubMed ID: 27388659
[TBL] [Abstract][Full Text] [Related]
20. Vortioxetine for depression in adults.
Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
